The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 231-241

  Movva, Sujana ^b   Verschraegen, Claire ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NONE

Author keywords

CTLA 4; Ipilimumab; MDX 010; Melanoma

Indexed keywords

ALPHA2B INTERFERON; BUDESONIDE; CA 125 ANTIGEN; CELL SURFACE MARKER; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DNA VACCINE; FOLLITROPIN; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA DR ANTIGEN; HYDROCORTISONE; INTERLEUKIN 2; IPILIMUMAB; LUTEINIZING HORMONE; MELAN A; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; MONTANIDE ISA 51; PEPTIDE VACCINE; PLACEBO; STEROID; TESTOSTERONE; THYROTROPIN; THYROXINE; TICILIMUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADRENAL CORTEX INSUFFICIENCY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE RASH; AUTOIMMUNITY; BLADDER CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COLITIS; COLON PERFORATION; CYTOKINE PRODUCTION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTROL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; ENTEROCOLITIS; FLOW CYTOMETRY; FOLLOW UP; HEPATITIS; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOTOXICITY; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MELANOMA CELL; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRACTICE GUIDELINE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RASH; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR REJECTION; UVEITIS; IMMUNOLOGY; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 66149084910     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802643347     Document Type: Review

References (63)

1. Middleton MR, Grob JJ, Aaronson N, et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-166 (Pubitemid 30036349)
2. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24(29):4738-4745 (Pubitemid 46630937)
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-2116
4. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(Suppl 1): S11-4 (Pubitemid 30117631)
5. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19(1):21-34 (Pubitemid 30305516)
6. Brogelli L, Reali UM, Moretti S, Urso C. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res 1992;2(2):87-91
7. Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410 (6832):1107-1111 (Pubitemid 32391043)
8. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997;158(5):1989-1993
9. van der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003;21:659-684 (Pubitemid 37174544)
10. Davis SJ, Ikemizu S, Evans EJ, et al. The nature of molecular recognition by T cells. Nat Immunol 2003;4(3):217-224 (Pubitemid 36322130)
11. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192(2):303-310 (Pubitemid 30470313)
12. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7(4):445-450 (Pubitemid 27508696)
13. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-252 (Pubitemid 32368035)
14. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995;7(5):682-686
15. Fujiwara H, Hamaoka T. Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Immunol Res 1995;14(4):271-291 (Pubitemid 26069160)
16. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-594 (Pubitemid 32368046)
17. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1(5):405-413 (Pubitemid 2134466)
18. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174(3):561-569
19. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987;328(6127):267-270
20. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182(2):459-465
21. Linsley PS, Greene JL, Brady W, et al. Human B7-1(CD80) and B7-2(CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1(9):793-801
22. Lindsten T, Lee KP, Harris ES, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993;151(7):3489-3499 (Pubitemid 23282661)
23. Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 2003;171(11):6251-6259 (Pubitemid 37467248)
24. Yang YF, Zou JP, Mu J, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997;57(18):4036-4041 (Pubitemid 27427694)
25. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734-1736 (Pubitemid 26102823)
26. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000;192(2):295-302 (Pubitemid 30470312)
27. Perrin PJ, Maldonado JH, Davis TA, et al. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996;157(4):1333-1336 (Pubitemid 126449068)
28. Luhder F, Hoglund P, Allison JP, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998;187(3):427-432 (Pubitemid 28080071)
29. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998;58(23):5301-5304 (Pubitemid 28551104)
30. Ariyan C, Salvalaggio P, Fecteau S, et al. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol 2003;171(11):5673-5677 (Pubitemid 37467180)
31. Greenwald RJ, Latchman YE, Sharpe AH. Negative co-receptors on lymphocytes. Curr Opin Immunol 2002;14(3):391-396 (Pubitemid 34327984)
32. van EA, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190 (3):355-366 (Pubitemid 29374833)
33. Gregor PD, Wolchok JD, Ferrone CR, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004;22(13-14):1700-1708 (Pubitemid 38447218)
34. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann Surg Oncol 2005;12(12):1005-1016 (Pubitemid 41660676)
35. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100 (14):8372-8377 (Pubitemid 36842552)
36. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23(25):6043-6053 (Pubitemid 46300222)
37. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23(4):741-750 (Pubitemid 46224173)
38. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29(4):455-463 (Pubitemid 44288958)
39. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005;175(11):7746-7754 (Pubitemid 41713475)
40. O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13(3):958-964 (Pubitemid 46340373)
41. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322(5899):271-275
42. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6(4):338-344 (Pubitemid 41716770)
43. Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106(11):2437-2444 (Pubitemid 43787668)
44. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13(22 Pt 1):6681-6688 (Pubitemid 350206804)
45. Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810-1815 (Pubitemid 46952950)
46. Dai D, Wu S, Parker M, et al. Model-based evaluation of ipilimumab dosage regimen in patients with advanced melanoma. American Society of Clinal Oncology Conference Abstract;2008
47. Thompson JA. Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma [abstract 9055]. J Clin Oncol 2008;26
48. Tchekmedyian S, Glasby J, Korman A et al.: MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma [abstract 56]. Proc Am Soc Clin Oncol 2002;21
49. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105(8):3005-3010 (Pubitemid 351723658)
50. Fischkoff SA, Hersh E, Weber J, et al. Durable responses and long-term progression-free survival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol 2005;23(Suppl 16)
51. Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration resitant prostate cancer [abstract 5004]. J Clin Oncol 2008;26S
52. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28(6):593-598 (Pubitemid 41533093)
53. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30 (8):825-830 (Pubitemid 350295361)
54. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4(3):321-327 (Pubitemid 28144091)
55. Gerritsen W, van den Eertwegh AJ, de Grujl T, et al. Expanded Phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). American Society of Clinical Oncology Annual Meeting;2008
56. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24(15):2283-2289 (Pubitemid 46630658)
57. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007;12(7):864-872 (Pubitemid 47328229)
58. Lin R, Yellin MJ, Lowy I, et al. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy. American Society of Clinical Oncology Annual Meeting;2008
59. Beck KE, Phillips JH, Greenbaum M, Chen B. CTLA-4 antibody in the SAIN tumor model when combined with dexamethasone. American Association for Cancer Research Annual Meeting Proceeding; 2007
60. Weber JS. Safety and efficacy of iplimumab with or without prophylacitc budesonide in the treatment-naive and previously treated patients with advanced melanoma. American Society of Clinical Oncology Annual Meeting; 2008
61. Hamid O, Urba WJ, Yellin M, et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma(abstract 8525). J Clin Oncol 2007;25(18S)
62. Hamid O, Chin K, Li J, et al. Dose effect of ipilimumab in patients with advaned melanoma: Results from a Phase II, randomized dose-ranging study [abstract 9025]. J Clin Oncol 2008;26(20S)
63. Weber JS, Hersh EM, Yellin M, et al. The efficacy and safety of ipilimumab (MDX-0101) in patients with unresectable stage III or stage IV malignant melanoma [abstract 8523]. J Clin Oncol 2008;26(20S)